Brivane

Brivane is a private biotechnology company focused on the discovery and development of next-generation small molecule therapeutics for oncology. The company specializes in targeting the RAS signaling pathway, which is one of the most frequently mutated pathways in human cancers. Brivane's lead programs are centered on developing highly selective inhibitors for KRAS mutations, including G12D and G12V, which have historically been challenging to target effectively. Their goal is to address significant unmet medical needs in patients with KRAS-mutant solid tumors, such as pancreatic and colorectal cancers. By leveraging advanced medicinal chemistry and structural biology, the company aims to provide transformative treatments for patients who have limited options.